Backovic, Dragana (55856937600)Dragana (55856937600)BackovicIgnjatovic, Svetlana (55901270700)Svetlana (55901270700)IgnjatovicRakicevic, Ljiljana (14047140100)Ljiljana (14047140100)RakicevicNovkovic, Mirjana (57191976429)Mirjana (57191976429)NovkovicTisma, Jelena Kusic (57191977168)Jelena Kusic (57191977168)TismaRadojkovic, Dragica (6602844151)Dragica (6602844151)RadojkovicStrugarevic, Evgenija (57188316600)Evgenija (57188316600)StrugarevicCalija, Branko (9739939300)Branko (9739939300)CalijaRadak, Djordje (7004442548)Djordje (7004442548)RadakKovac, Mirjana (7102654168)Mirjana (7102654168)Kovac2025-07-022025-07-022016https://doi.org/10.2174/1570161114666160714103148https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995584818&doi=10.2174%2f1570161114666160714103148&partnerID=40&md5=eadb155ac7ab97570ea054faca7a0c8chttps://remedy.med.bg.ac.rs/handle/123456789/13338Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA). Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days. Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p<0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR. Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel-HTPR in patients with carotid artery stenosis undergoing CEA. © 2016 Bentham Science Publishers.Carotid artery stenosisCarotid endarterectomyClopidogrelPlatelet reactivityRisk factors